GlassScriptPhysician profile
Ji Eun Paik
NPI 1528162021
$2,835.13
in general payments reported to CMS, 2019-2025
28 companies · $543 in 2025
The $543 reported for 2025 was more than what 82% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $360 · 2020: $48.80 · 2021: $12.31 · 2022: $822 · 2023: $649 · 2024: $401 · 2025: $543.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,592.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,591.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $447.66 | 2019-2025 | Veozah |
| Pfizer INC. | $291.05 | 2019-2024 | |
| Mayne Pharma Commercial LLC | $263.41 | 2022-2025 | |
| Abbvie INC. | $248.37 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $191.56 | 2023-2025 | Myfembree, Gemtesa |
| Millicent US INC | $172.48 | 2019-2025 | Femring, Intrarosa, Femlyv |
| Coopersurgical, INC. | $168.11 | 2019-2025 | Paragard T 380a, Paragard T 380a, Endosee |
| Exeltis, USA INC. | $125.44 | 2020-2025 | Slynd |
| Myovant Sciences INC. | $118.38 | 2022 | |
| Gynesonics, INC. | $110.08 | 2022 | |
| Therapeuticsmd, INC. | $83.25 | 2019-2022 | |
| Sage Therapeutics, LLC | $72.58 | 2025 | Zurzuvae |
| Bayer Healthcare Pharmaceuticals INC. | $69.57 | 2019-2025 | |
| Renovia INC | $64.91 | 2019 | |
| Myriad Women'S Health, INC. | $61.28 | 2023 | Myrisk |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $57.70 | 2023-2025 | Cologuard Collection Kit |
| Avion Pharmaceuticals | $49.58 | 2022 | |
| Organon LLC | $31.18 | 2022-2023 | Nexplanon |
| Vertical Pharmaceuticals, LLC | $30.62 | 2019 | |
| Aspira Women'S Health INC | $24.30 | 2023 | Ova1 |
| Becton, Dickinson and Company | $24.23 | 2019 | |
| Optumhealth Care Solutions, LLC | $23.69 | 2025 | Vivify Health Care Team Portal 001, Eitan Medical |
| Duchesnay USA Incorporated | $19.44 | 2019 | |
| Supernus Pharmaceuticals, INC. | $18.75 | 2025 | Qelbree |
| Mylan Pharmaceuticals INC. | $18.65 | 2022 | |
| Amag Pharmaceuticals, INC. | $18.48 | 2019 | |
| Aesculap, INC. | $15.25 | 2019 | |
| Lupin INC. | $15.13 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ji Eun Paik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.